Loughborough University The Centre for Biological Engineering	Acquis	Acquisition and Receipt of Biological Materials					
Doc Ref: FS008.1 : HTA-PR-FORM/007	Version N°:	1.0	Issue Date:				

ARF No: CBE/ARF/000 62

A1. Details of Sample/Specimen							
						⊠Human	
Type/ID: (eg primary cell, cell line, tissu fluid, excreta, biological agent)	e, body Human	Human Cord Blood (Ficolled) CD34+ isolation				□Animal	
Format / Quantity: (eg vials, slides, e	tc) 4x50mL	4x50mL tube containing ~21mL ficol unit. 4 donors total					
Tissue site/Organ source:	Cord Blo	Cord Blood				□N/A	
Batch N°:	7	8					
Is the sample/specimen consider If No, go to section A2.	ed to be Relevar	nt Material under th	e Human Tis	ssue Act (HTA)?		⊠Yes □No	
Is the material obtained from an	HTA licenced Tis	sue Bank with REC	approval for	generic research	use?	⊠Yes □No	
Is the material obtained for stora	ge and use unde	er a project specific	NHS REC app	oroval?		□Yes □No	
Is the material licensable under the HTA? Indicate source below:					⊠Yes □No		
	Commercial Supp	olier 🗆 Imported (f	rom outside	England, Wales	or N.Ireland)		
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID	Lot N°: G2212	Lot N°: G221222200314, 238, 195, 330			Assigned Unique ID (Procuro): S00247458, 59, 60, 61, 62		
If Yes, provide Project Ref N°:	BRA060	BRA060 & BRA010					
If Yes, provide the name of the P	Dr Rob	Dr Rob Thomas					
A2. Details of Receipt							
Date/Time of receipt	Date	24/03/2022	24/03/2022		16:00		
ID of Receiver	Name:	Jon Harrima	Jon Harriman		CBE		
ID of Supplier/Provider	Name:	Anthony Nol	Anthony Nolan		UK		
PART B: To be completed by the	Receiver						
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		s ⊠Yes □No	Ref Num	Ref Number: BRA060 & BRA010			
Physical integrity of the material(s) acceptable?		. ⊠Yes □No	If No, de	If No, describe action taken			
Quantity received correct?		⊠Yes □No	If No, de	If No, describe action taken			
Labelling correct and legible?		⊠Yes □No	If No, de	If No, describe action taken			
Is the relevant documentation	C of A or equiv	A or equivalent evidence of ty		⊠Yes □No □N/A			
attached to this form?	Agreements to	eements to enable transfer of terial eg MTA, SLA		No □N/A	*		
If No, add reference or details to ensure traceability	Details/evider	Details/evidence/assurance of consent		⊠Yes □No □N/A			

	Other (describe)	☐Yes ☐No ☐N/A	
Temporary storage - Quarantine location (as applicable)	Building/Room	After processing (H21) wil		and processed immediately. I be frozen via passive cooling ntil 25/03/22 and transferred
	Storage Unit ID			
	Within storage	Within storage unit location ID Bank 7 Rack 5 Box A 1, 2, 3,		3. 4. 5
	Date/Time of quarantine 25/03/2022 12:00			
Submitted by:	Signature:		Date: 24/3/22	
PART C: To be completed by the	e departmental Q	uality Manager		
C1. Quality Assurance Checks				
Has the sample/specimen been	☐Yes ☐No ☐N/A			
Has the donor been screened for	□Yes □No □N/A			
Has the sample/specimen been	□Yes □No □N/A			
Is there evidence that the suppli- or other recognised certification	□Yes □No □N/A			
For HTA licensable material, is there sufficient evidence to support the requirements for storage and use of the material under the University's HTA Research Licence?				□Yes □No □N/A
Is there sufficient evidence to su	□Yes □No □N/A			
C2. Approval for release from qu	uarantine			
Can the material be released fro released for processing?	m quarantine and	transferred to desi	gnated storage area or	☑Yes □No
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Accept as is, but with extra controls		
		☐ Rework or reprocess to meet the specified requirements		
		☐Test to meet specified requirements		, , , , , , , , , , , , , , , , , , ,
		☐Return to supplier/provider		
		□Disposal		
		Building/Room		
If Yes, provide details of storage location (applicable)		Storage Unit ID		
	location (as	Within storage unit location ID		As above.
		Database Reference		
		Date/Time of transfer		9
Approved by:		Signature:	Cill	Date: 28/1/22.